For example, the concurrent blockade of PD-1 and lymphocyte-activation gene 3 (LAG-3) has enhanced the cytotoxic function of CD8+T cells in melanoma patients, improving therapeutic outcomes [18, 19]. This evidence concerns the gene LAG3 and melanoma.